Sponsor

Centocor, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Centocor, Inc. appears in 34 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials34
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

34 shown
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT01248780 · lead sponsor · 2010-09-01
COMPLETED
A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With AsthmaNCT01195207 · lead sponsor · 2010-06-01
COMPLETED
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyNCT00973479 · lead sponsor · 2009-09-01
COMPLETED
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsNCT00841191 · lead sponsor · 2009-03-01
COMPLETED
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes MellitusNCT00882726 · lead sponsor · 2009-02-01
COMPLETED
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00718718 · lead sponsor · 2008-08-11
COMPLETED
A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent AsthmaNCT00675649 · lead sponsor · 2008-05-01
WITHDRAWN
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)NCT01362153 · lead sponsor · 2007-12-26
COMPLETED
A Study to Test the Design, Functionality, and Ergonomic Features of the AutoinjectorNCT00643526 · lead sponsor · 2007-12-01
COMPLETED
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate CancerNCT00537381 · lead sponsor · 2007-05-01
COMPLETED
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)NCT00385827 · lead sponsor · 2006-11-01
TERMINATED
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00361335 · lead sponsor · 2006-09-01
COMPLETED
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).NCT00380796 · lead sponsor · 2006-04-01
COMPLETED
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)NCT00299546 · lead sponsor · 2006-02-01
COMPLETED
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00264550 · lead sponsor · 2005-12-01
COMPLETED
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naiveNCT00264537 · lead sponsor · 2005-12-01
COMPLETED
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate CancerNCT00401765 · lead sponsor · 2005-09-01
COMPLETED
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent AsthmaNCT00207740 · lead sponsor · 2004-08-01
COMPLETED
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple SclerosisNCT00207727 · lead sponsor · 2004-07-01
COMPLETED
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid ArthritisNCT00207714 · lead sponsor · 2003-11-01
COMPLETED
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPDNCT00056264 · lead sponsor · 2002-12-01
COMPLETED
A Long-term Safety Study of Infliximab (Remicade)NCT00261976 · lead sponsor · 2002-02-01
COMPLETED
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid ArthritisNCT00036374 · lead sponsor · 2001-10-01
COMPLETED
Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisNCT00269867 · lead sponsor · 1997-03-01
COMPLETED
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.NCT00036387 · lead sponsor
COMPLETED
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid ArthritisNCT00236028 · lead sponsor
COMPLETED
Bronchoscopy Study for Severe AsthmaNCT01745809 · collaborator · 2013-01-01
WITHDRAWN
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory ArthritisNCT00796809 · collaborator · 2007-10-01
COMPLETED
Centocor Microarray Study of PatientsNCT00462072 · collaborator · 2007-03-01
COMPLETED
Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) PopulationNCT00431405 · collaborator · 2006-08-01
UNKNOWN
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)NCT00727298 · collaborator · 2006-02-01
COMPLETED
The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid ArthritisNCT00327275 · collaborator · 2004-03-01
COMPLETED
Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)NCT00725621 · collaborator · 2004-03-01
COMPLETED
Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From CachexiaNCT00244192 · collaborator · 2003-10-01
COMPLETED

Drugs studied in this sponsor's trials

8 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Centocor, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo9
infliximab6
golimumab5
methotrexate4
docetaxel2
prednisone2
mitoxantrone1
siltuximab1
placebo RxCUI 8375 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 9 trials infliximab RxCUI 191831 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 6 trials golimumab RxCUI 819300 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials methotrexate RxCUI 6851 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials docetaxel RxCUI 72962 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials prednisone RxCUI 8640 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials mitoxantrone RxCUI 7005 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial siltuximab RxCUI 1535218 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor26
collaborator8
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.